Eli Lilly and Stock Price, News & Analysis (NYSE:LLY)

$86.21 0.92 (1.08 %)
(As of 01/18/2018 05:10 AM ET)
Previous Close$85.29
Today's Range$85.47 - $86.36
52-Week Range$74.00 - $89.09
Volume4.08 million shs
Average Volume3.06 million shs
Market Capitalization$94.93 billion
P/E Ratio41.05
Dividend Yield2.39%
Beta0.35

About Eli Lilly and (NYSE:LLY)

Eli Lilly and logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:LLY
CUSIP53245710
Phone+1-317-2762000

Debt

Debt-to-Equity Ratio0.66%
Current Ratio1.38%
Quick Ratio1.03%

Price-To-Earnings

Trailing P/E Ratio41.052380952381
Forward P/E Ratio20.43
P/E Growth1.63

Sales & Book Value

Annual Sales$21.22 billion
Price / Sales4.47
Cash Flow$4.70 per share
Price / Cash18.35
Book Value$12.76 per share
Price / Book6.76

Profitability

Trailing EPS$2.10
Net Income$2.74 billion
Net Margins9.90%
Return on Equity30.27%
Return on Assets10.82%

Miscellaneous

Employees41,975
Outstanding Shares1,101,090,000

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, December 11th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share on Friday, March 9th. This represents a $2.25 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and's previous quarterly dividend of $0.52. View Eli Lilly and's Dividend History.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Co (NYSE:LLY) released its quarterly earnings data on Tuesday, October, 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.03 by $0.02. The business earned $5.66 billion during the quarter, compared to analysts' expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business's revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.88 EPS. View Eli Lilly and's Earnings History.

When will Eli Lilly and make its next earnings announcement?

Eli Lilly and is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Eli Lilly and.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and updated its FY18 earnings guidance on Wednesday, December, 13th. The company provided earnings per share (EPS) guidance of $4.60-4.70 for the period, compared to the Thomson Reuters consensus estimate of $4.65. The company issued revenue guidance of $23.0-23.5 billion, compared to the consensus revenue estimate of $23.07 billion.Eli Lilly and also updated its FY17 guidance to $4.15-4.25 EPS.

Where is Eli Lilly and's stock going? Where will Eli Lilly and's stock price be in 2018?

15 analysts have issued 12-month price objectives for Eli Lilly and's stock. Their forecasts range from $73.00 to $115.00. On average, they anticipate Eli Lilly and's stock price to reach $94.60 in the next year. View Analyst Ratings for Eli Lilly and.

What are Wall Street analysts saying about Eli Lilly and stock?

Here are some recent quotes from research analysts about Eli Lilly and stock:

  • 1. According to Zacks Investment Research, "Lilly’s third-quarter 2017 results were strong with the company beating estimates on both counts. Lilly also raised its sales and earnings outlook for the second time this year mainly backed by strong uptake trends of new products. Lilly is also exploring strategic alternatives for the Animal Health business, a prudent decision in our view. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. However, key drug Alimta will continue to be impacted by competition. Meanwhile, the recent high-profile pipeline setbacks, competition from immuno-oncology agents, loss of exclusivity for many drugs, and weak performance of the Animal Health segment this year are an investor concern." (10/30/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS Group AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and's key competitors?

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer (Age 49)
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories (Age 63)
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer (Age 48)
  • Michael J. Harrington, Senior Vice President, General Counsel (Age 54)
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity (Age 51)
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA (Age 50)
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications (Age 58)
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications
  • Jeffrey N. Simmons, Senior Vice President and President - Elanco Animal Health (Age 49)

Who owns Eli Lilly and stock?

Eli Lilly and's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Lilly Endowment Inc. (11.18%), Bank of Montreal Can (0.42%), Schwab Charles Investment Management Inc. (0.39%), Hexavest Inc. (0.12%), National Pension Service (0.07%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Eli Lilly and stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and.

Who sold Eli Lilly and stock? Who is selling Eli Lilly and stock?

Eli Lilly and's stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., DnB Asset Management AS, Atria Investments LLC, Exxonmobil Investment Management Inc. TX, First Citizens Bank & Trust Co., NEXT Financial Group Inc, First National Trust Co and Private Capital Advisors Inc.. Company insiders that have sold Eli Lilly and company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and.

Who bought Eli Lilly and stock? Who is buying Eli Lilly and stock?

Eli Lilly and's stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., Pensionfund DSM Netherlands, Nisa Investment Advisors LLC, National Pension Service, Pensionfund Sabic, Hexavest Inc. and Waverton Investment Management Ltd. Company insiders that have bought Eli Lilly and stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and.

How do I buy Eli Lilly and stock?

Shares of Eli Lilly and can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and's stock price today?

One share of Eli Lilly and stock can currently be purchased for approximately $86.21.

How big of a company is Eli Lilly and?

Eli Lilly and has a market capitalization of $94.93 billion and generates $21.22 billion in revenue each year. The company earns $2.74 billion in net income (profit) each year or $2.10 on an earnings per share basis. Eli Lilly and employs 41,975 workers across the globe.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is Lilly Corporate Ctr, Drop Code 1112, INDIANAPOLIS, IN 46285, United States. The company can be reached via phone at +1-317-2762000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly and (LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  740 (Vote Outperform)
Underperform Votes:  562 (Vote Underperform)
Total Votes:  1,302
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eli Lilly and (NYSE:LLY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.532.532.502.63
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $94.60$91.60$90.00$88.67
Price Target Upside: 8.76% upside5.64% upside3.99% upside6.01% upside

Eli Lilly and (NYSE:LLY) Consensus Price Target History

Price Target History for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Jefferies GroupSet Price TargetBuy$100.00HighView Rating Details
1/16/2018Goldman Sachs GroupDowngradeBuy -> Neutral$86.98 -> $95.00HighView Rating Details
1/5/2018ArgusUpgradeHold -> Buy$85.52 -> $115.00MediumView Rating Details
12/13/2017Credit Suisse GroupReiterated RatingHoldMediumView Rating Details
12/12/2017BMO Capital MarketsSet Price TargetSell$73.00LowView Rating Details
11/21/2017Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$86.00 -> $90.00N/AView Rating Details
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$92.00 -> $93.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetOverweight$90.00 -> $98.00N/AView Rating Details
10/4/2017CowenReiterated RatingBuy$95.00LowView Rating Details
7/26/2017OppenheimerDowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/17/2017Deutsche BankReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/4/2017CitigroupReiterated RatingBuy$100.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
11/26/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust BanksReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Eli Lilly and (NYSE:LLY) Earnings History and Estimates Chart

Earnings by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE LLY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$1.07N/AView Earnings Details
10/24/2017Q3 2017$1.03$1.05$5.52 billion$5.66 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.60 billion$5.82 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
10/21/2010Q3 2010$1.15$1.21ViewN/AView Earnings Details
7/22/2010Q2 2010$1.11$1.24ViewN/AView Earnings Details
4/19/2010Q1 2010$1.11$1.18ViewN/AView Earnings Details
1/28/2010Q4 2009$0.92$0.91ViewN/AView Earnings Details
10/21/2009Q3 2009$1.02$1.20ViewN/AView Earnings Details
7/22/2009Q2 2009$1.02$1.12ViewN/AView Earnings Details
4/20/2009Q1 2009$0.99$1.20ViewN/AView Earnings Details
1/29/2009Q4 2008$1.05$1.07ViewN/AView Earnings Details
10/23/2008Q3 2008$1.01$1.04ViewN/AView Earnings Details
7/24/2008Q2 2008$0.99$0.99ViewN/AView Earnings Details
4/21/2008Q1 2008$0.95$0.92ViewN/AView Earnings Details
1/29/2008Q4 2007$0.89$0.90ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Eli Lilly and (NYSE:LLY) Earnings Estimates

2018 EPS Consensus Estimate: $4.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.09$1.09$1.09
Q2 20181$1.22$1.22$1.22
Q3 20181$1.22$1.22$1.22
Q4 20181$1.14$1.14$1.14
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Eli Lilly and (NYSE:LLY) Dividend Information

Next Dividend:3/9/2018
Annual Dividend:$2.08
Dividend Yield:2.41%
Dividend Growth:2.00% (3 Year Average)
Payout Ratio:99.05% (Trailing 12 Months of Earnings)
49.29% (Based on This Year's Estimates)
44.83% (Based on Next Year's Estimates)
Track Record:3 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2017quarterly$0.562.59%2/14/20182/15/20183/9/2018
10/16/2017quarterly$0.522.42%11/14/201711/15/201712/8/2017
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Eli Lilly and (NYSE LLY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 76.35%
Insider Trades by Quarter for Eli Lilly and (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE LLY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2017Lilly Endowment IncMajor ShareholderSell200,000$88.20$17,640,000.00123,084,104View SEC Filing  
12/11/2017Jeffrey N SimmonsSVPSell12,500$86.46$1,080,750.00124,522View SEC Filing  
12/4/2017Susan MahonySVPSell36,585$86.18$3,152,895.3054,885View SEC Filing  
11/10/2017Alfonso G ZuluetaSVPSell2,003$83.67$167,591.0143,580View SEC Filing  
10/4/2017Lilly Endowment IncMajor ShareholderSell205,000$86.81$17,796,050.00View SEC Filing  
9/29/2017Lilly Endowment IncMajor ShareholderSell195,000$85.14$16,602,300.00123,513,247View SEC Filing  
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00123,682,287View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00123,865,804View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00124,049,283View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00124,265,804View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00124,475,804View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.0014,041View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.0162,056View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00114,217View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00124,690,804View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00125,125,804View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.0045,583View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.6858,443View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00886View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00125,359,047View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00125,649,408View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.398,169View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.0033,504View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.3067,802View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.7694,319View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.3942,306View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.2042,110View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00125,775,804View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.081,300View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00126,020,570View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00126,220,804View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00126,442,509View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00126,808,704View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00126,963,785View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.8410,710View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00127,090,804View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.0040,600View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00127,295,910View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.003,113View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00127,481,005View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.0045,101View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00127,660,804View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.1059,690View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.7879,403View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.7436,931View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.4039,487View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.0057,101View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00127,860,804View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00128,065,804View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.0088,131View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00128,280,804View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00128,490,804View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00128,695,804View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00128,895,804View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00129,110,804View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00129,370,804View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00134,690,804View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.8332,180View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00134,920,804View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00135,130,804View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00135,320,804View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00135,520,804View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.0057,177View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eli Lilly and (NYSE LLY) News Headlines

Source:
DateHeadline
A Rally in Eli Lilly Could Heal Traders, InvestorsA Rally in Eli Lilly Could Heal Traders, Investors
finance.yahoo.com - January 17 at 5:00 PM
U.S. Senate committee advances Azar nomination as health secretaryU.S. Senate committee advances Azar nomination as health secretary
finance.yahoo.com - January 17 at 5:00 PM
Key U.S. Senate committee advances Azar nomination for HHS secretaryKey U.S. Senate committee advances Azar nomination for HHS secretary
finance.yahoo.com - January 17 at 5:00 PM
Is Eli Lilly and Company a Buy in 2018?Is Eli Lilly and Company a Buy in 2018?
finance.yahoo.com - January 17 at 9:52 AM
Big Pharma: Merck Zooms, Eli Lilly LagsBig Pharma: Merck Zooms, Eli Lilly Lags
finance.yahoo.com - January 16 at 4:53 PM
Eli Lilly and (LLY) Given a $100.00 Price Target at Jefferies GroupEli Lilly and (LLY) Given a $100.00 Price Target at Jefferies Group
www.americanbankingnews.com - January 16 at 9:34 AM
Lilly's Elanco/Aratana's Veterinary Medicine Gets EU NodLilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
finance.yahoo.com - January 12 at 10:02 AM
Elanco Announces Addition of New North America and Global Strategy Senior ExecutiveElanco Announces Addition of New North America and Global Strategy Senior Executive
finance.yahoo.com - January 11 at 5:01 PM
How Mylan’s Rest of the World Segment Performed in 3Q17How Mylan’s Rest of the World Segment Performed in 3Q17
finance.yahoo.com - January 11 at 10:18 AM
Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in EuropeElanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe
finance.yahoo.com - January 11 at 10:18 AM
Eli Lilly & Co. (LLY) Announces Collaboration with Livongo on Real-World Diabetes Research - StreetInsider.comEli Lilly & Co. (LLY) Announces Collaboration with Livongo on Real-World Diabetes Research - StreetInsider.com
www.streetinsider.com - January 10 at 10:04 AM
U.S. pharma executives expect deals to pick up after tax overhaul - ReutersU.S. pharma executives expect deals to pick up after tax overhaul - Reuters
www.reuters.com - January 10 at 10:04 AM
Eli Lilly CEO Says Tax Reform May Lead to More Successful Deals - BloombergEli Lilly CEO Says Tax Reform May Lead to More Successful Deals - Bloomberg
www.bloomberg.com - January 10 at 10:04 AM
HHS nominee Azar challenged over rising drug prices at company he ranHHS nominee Azar challenged over rising drug prices at company he ran
www.usatoday.com - January 9 at 4:58 PM
Eli Lilly CEO on Drug Pricing and Diabetes Treatment - Presented by: The Aol. On NetworkEli Lilly CEO on Drug Pricing and Diabetes Treatment - Presented by: The Aol. On Network
www.nasdaq.com - January 9 at 4:58 PM
Eli Lilly CEO Says Industry Needs Pricing InnovationEli Lilly CEO Says Industry Needs Pricing Innovation
www.msn.com - January 9 at 4:58 PM
Eli Lilly CEO on Drug Pricing and Diabetes TreatmentEli Lilly CEO on Drug Pricing and Diabetes Treatment
finance.yahoo.com - January 9 at 4:58 PM
Eli Lilly CEO Says Drug Pricing Innovation Is NeededEli Lilly CEO Says Drug Pricing Innovation Is Needed
finance.yahoo.com - January 9 at 4:58 PM
Health secretary nominee indicates support for Medicaid overhaulHealth secretary nominee indicates support for Medicaid overhaul
finance.yahoo.com - January 9 at 4:58 PM
Trump health pick wary of government drug price negotiationsTrump health pick wary of government drug price negotiations
marketbeat.com - January 9 at 12:55 PM
Eli Lilly and Co (LLY) Receives Consensus Rating of "Hold" from AnalystsEli Lilly and Co (LLY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 8 at 6:04 PM
Eli Lilly & Co. (LLY) Announces Collaboration with Livongo on Real-World Diabetes ResearchEli Lilly & Co. (LLY) Announces Collaboration with Livongo on Real-World Diabetes Research
www.streetinsider.com - January 8 at 5:00 PM
Eli Lilly CEO Says Tax Reform May Lead to More Successful DealsEli Lilly CEO Says Tax Reform May Lead to More Successful Deals
finance.yahoo.com - January 8 at 5:00 PM
Livongo and Lilly Collaborate on Real-World Diabetes ResearchLivongo and Lilly Collaborate on Real-World Diabetes Research
finance.yahoo.com - January 8 at 10:10 AM
Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018
finance.yahoo.com - January 8 at 10:10 AM
Argus Shares Eli Lillys Optimism, Upgrades To BuyArgus Shares Eli Lilly's Optimism, Upgrades To Buy
finance.yahoo.com - January 6 at 9:57 AM
Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results AnnouncementLilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement
finance.yahoo.com - January 5 at 10:05 AM
Eli Lilly and (LLY) Raised to Buy at ArgusEli Lilly and (LLY) Raised to Buy at Argus
www.americanbankingnews.com - January 5 at 8:14 AM
How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?
finance.yahoo.com - January 4 at 4:55 PM
$5.96 Billion in Sales Expected for Eli Lilly and Co (LLY) This Quarter$5.96 Billion in Sales Expected for Eli Lilly and Co (LLY) This Quarter
www.americanbankingnews.com - January 4 at 6:56 AM
Made in China: New and potentially lifesaving drugsMade in China: New and potentially lifesaving drugs
www.bizjournals.com - January 3 at 4:56 PM
Analysts’ Recommendations for Eli Lilly in December 2017Analysts’ Recommendations for Eli Lilly in December 2017
finance.yahoo.com - January 3 at 4:56 PM
Analysts’ Estimates for Eli LillyAnalysts’ Estimates for Eli Lilly
finance.yahoo.com - January 3 at 8:59 AM
Eli Lilly’s Elanco in 3Q17Eli Lilly’s Elanco in 3Q17
finance.yahoo.com - January 2 at 5:56 PM
Lilly to Present at J.P. Morgan Healthcare ConferenceLilly to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 5:56 PM
Trump FDA Chief Scott Gottlieb Isnt Pharmas BFF After All - BloombergTrump FDA Chief Scott Gottlieb Isn't Pharma's BFF After All - Bloomberg
www.bloomberg.com - January 2 at 9:53 AM
Eli Lilly’s Neuroscience Products Portfolio in 3Q17Eli Lilly’s Neuroscience Products Portfolio in 3Q17
finance.yahoo.com - January 2 at 9:53 AM
Eli Lilly’s Cardiovascular Products Portfolio in 3Q17Eli Lilly’s Cardiovascular Products Portfolio in 3Q17
finance.yahoo.com - January 1 at 4:49 PM
Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : January 1, 2018Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : January 1, 2018
finance.yahoo.com - January 1 at 9:52 AM
Eli Lilly’s New Products Portfolio in 3Q17Eli Lilly’s New Products Portfolio in 3Q17
finance.yahoo.com - January 1 at 9:52 AM
Eli Lilly’s Endocrine Product Portfolio in 3Q17Eli Lilly’s Endocrine Product Portfolio in 3Q17
finance.yahoo.com - January 1 at 9:52 AM
Learn From My Portfolio Mistakes: Cramers Mad Money Recap (Friday 12/29/17)Learn From My Portfolio Mistakes: Cramer's 'Mad Money' Recap (Friday 12/29/17)
finance.yahoo.com - December 30 at 9:45 AM
Eli Lilly’s Revenue Trend in 3Q17Eli Lilly’s Revenue Trend in 3Q17
finance.yahoo.com - December 29 at 4:51 PM
ETFs with exposure to Eli Lilly & Co. : December 29, 2017ETFs with exposure to Eli Lilly & Co. : December 29, 2017
finance.yahoo.com - December 29 at 4:51 PM
Eli Lilly’s Business Segments in 3Q17Eli Lilly’s Business Segments in 3Q17
finance.yahoo.com - December 29 at 4:51 PM
Merck & Co., Inc. (MRK) and Eli Lilly and (LLY) Head to Head ReviewMerck & Co., Inc. (MRK) and Eli Lilly and (LLY) Head to Head Review
www.americanbankingnews.com - December 29 at 9:30 AM
Is It Time To Sell Eli Lilly and Company (NYSE:LLY) Based Off Its PE Ratio?Is It Time To Sell Eli Lilly and Company (NYSE:LLY) Based Off Its PE Ratio?
finance.yahoo.com - December 27 at 5:44 PM
Biogen's Alzheimer's Drug Misses Goal in Interim AnalysisBiogen's Alzheimer's Drug Misses Goal in Interim Analysis
finance.yahoo.com - December 22 at 10:06 AM
Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
www.fool.com - December 22 at 8:42 AM
FDA OKs Mercks ertugliflozin/sitagliptin for T2D - Seeking AlphaFDA OKs Merck's ertugliflozin/sitagliptin for T2D - Seeking Alpha
seekingalpha.com - December 20 at 4:53 PM

SEC Filings

Eli Lilly and (NYSE:LLY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eli Lilly and (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eli Lilly and (NYSE LLY) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.